SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): September 24, 1997
(September 23, 1997)
LASERSIGHT INCORPORATED
-----------------------
Exact name of registrant as specified in its charter
Delaware
--------
State or other jurisdiction of incorporation
0-19671 65-0273162
------- ----------
Commission File Number I.R.S. Employer
Identification No.
12161 Lackland Road, St. Louis, Missouri 63146
----------------------------------------------
Address of Principal Executive Offices
Registrant's telephone number, including area code: (314) 469-3220
<PAGE>
Item 5. Other Events.
The press release issued by LaserSight Incorporated dated September 23, 1997 is
incorporated by reference herein.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit 99. Press Release dated September 23, 1997
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LaserSight Incorporated
Date: September 24, 1997 By: /s/ Michael R. Farris
-------------------------
Michael R. Farris
Chief Executive Officer
EXHIBIT 99
NASDAQ SYMBOL: LASE
LASERSIGHT RECEIVES $4 MILLION FOR EXCLUSIVE LICENSE
----------------------------------------------------
St. Louis, MO -- September 23, 1997 -- LaserSight Incorporated (NASDAQ: LASE)
today announced it has received a one-time lump sum payment of $4 million from a
third party in exchange for an exclusive worldwide royalty-free patent license
covering the vascular and cardiovascular rights included in the patents recently
acquired from International Business Machines Corporation (NYSE: IBM).
"This license agreement demonstrates the importance and value of what we have
acquired from IBM," said Michael R. Farris, president and chief executive
officer of LaserSight. "We are pursuing and in discussions with a number of
other potential licensees in both the ophthalmic and non-ophthalmic fields. The
patent claims are not limited to the ophthalmic field; therefore, all medical
specialties using excimer lasers are potential licensees."
Under the terms of the company's recent financing to purchase the IBM patents,
LaserSight may redeem up to 70 percent of the preferred shares outstanding. The
company is currently reviewing the amount to be redeemed and the timing of such.
LaserSight Incorporated is a holding company with operating subsidiaries engaged
in the business of ophthalmic laser manufacturing and international sales,
third-party managed vision care administration, ophthalmic practice management,
and health and vision care consulting services.
This press release contains forward-looking statements regarding future events
and future performance of the Company which involve risks and uncertainties that
could materially affect actual results. Investors should refer to documents the
Company files from time to time with the Securities and Exchange Commission for
a description of certain factors which could cause actual results to vary from
current expectations and the forward-looking statements contained in this press
release. Such filings include, without limitation, the Company's Form 10-K, Form
10-Q and Form 8-K reports.
For additional information please contact: Marti Benfield
Manager, Investor Relations
LaserSight Incorporated
(314) 469-3220
Visit us on the Internet at
www.lase.com
